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N-methyl-D-asparticacidreceptor(NMDAr)activationrequiresthepresenceofD-serine,synthesizedfromL-serinebyapyridoxal
5 -phosphate-dependent serine racemase (SR). D-serine levels can be lowered by inhibiting the racemization of L-serine. L-
serine-O-sulfate (LSOS) and L-erythro-3-hydroxyaspartate (LEHA), among others, have proven to be eﬀective in reducing the
D-serine levels in culture cells. It is tempting then to try these compounds in their eﬀectiveness to decrease nociceptive levels in
rat arthritic pain. We measured the C-reﬂex paradigm and wind-up potentiation in the presence of intrathecally injected LSOS
(100μg/10μL) and LEHA (100μg/10μL) in normal and monoarthritic rats. Both compounds decreased the wind-up activity in
normal and monoarthritic rats. Accordingly, all the antinociceptive eﬀects were abolished when 300μg/10μL of D-serine were
injected intrathecally. Since no in vivo results have been presented so far, this constitutes the ﬁrst evidence that SR inhibitions
lower the D-serine levels, thus decreasing the NMDAr activity and the consequent development and maintenance of chronic pain.
1.Introduction
D-serine, a coagonist of the glycine site of the NMDAr,
have been involved in many neurodegenerative disorders,
in which pathological overactivation of the receptor results
in neurotoxicity, as revealed by studies performed in cell
cultures and observed in the Alzheimer disease. The overac-
tivation of the NMDAr contributes also to acute disorders
as ischemia [1]. In the in vitro studies, D-serine induced
cytotoxicity in hippocampal slice cultures, since the removal
of endogenous D-serine completely abolishes NMDA neuro-
toxicity. In serine racemase KO mice (SR-KO), around 90%
decrease in forebrain D-serine content has been observed,
and in parallel, a reduced neurotoxicity induced by both
NMDA and β-Amyloid1-42 forebrain SR-KO mice injection
was found. The former strongly suggest that SR is the
responsible for the major D-serine production (Ran Inoue).
Microglia culture cells exposed to amyloid β-peptide as a
proinﬂammatory stimuli elicited a release of glutamate. This
activated microglia express SR, and thereby release D-serine,
contributing to the neurotoxicity found in inﬂammatory
conditions in the brain, and also in the Alzheimer’s disease
where SR RNA was elevated [2]. Regarding D-serine degra-
dation, it is performed by the D-amino acid oxidase, thus
contributingtotheD-serinehomeostasis[3].Anothermech-
anism proposed to be responsible of D-serine modulation is
gated by NMDAr activation, promoting the translocation of
SR to the plasma membrane, thus reducing enzyme activity
[4]. In brain areas where D-amino acid oxidase is poorly
expressed or absent, (forebrain areas) degradation of D-
serine is accomplished by a self-degradation mechanism by
the α, β-elimination of water [5]. A cell line (HEK293)
expressing mouse serine racemase was used to test L-serine-
O-sulfate as an alternative substrate. The authors found
that the degradation of L-serine-O-sulfate (to pyruvate and
ammonia) was two or three orders of magnitude faster2 The Scientiﬁc World Journal
than the L-serine racemization. Also, they demonstrated the
pharmacological inhibition of D-serine synthesis in cultured
astrocytes, thus providing a strategy to selectively decrease
NMDAr activation [6].
2.MaterialandMethods
2.1. Animals. Male Sprague-Dawley rats weighing 280–320g
were utilized in the present study. The ethical standards and
guidelines for researchers on experimental animal pain were
according to the Ethical Committee from the University of
Santiago of Chile and the Committee for Research in Ethical
Issues of the IASP, 1983 [7].
2.2. Rat Monoarthritic Model. For the monoarthritic rat
model, complete Freund’s adjuvant was prepared by adding
60mg of killed Mycobacterium butyricum (Difco Laborato-
ries, USA) bacteria to a mixture of 6mL paraﬃno i l ,4m L
of NaCl 0.9% and 1mL of Tween 80. The mixed suspension
was then autoclaved for 20min at 120◦C., to rupture the
mycobacterium cell walls. In order to induce the mono-
arthritis, the rats were injected 0.05mL of the complete
Freund’s adjuvant into the left tibiotarsal joint under a brief
halothane anesthesia. Control rats were given 0.05mL of the
vehicle used to suspend mycobacteria [8].
2.3. Drug Administration. Chemicals and their sources
were as follows: L-serine-O-sulfate (LSOS) from Sigma, L-
erythro-3-hydroxyaspartate(LEHA)fromWakoChem.Both
LSOS and LEHA were dissolved in saline (0.9% NaCl)
and injected intrathecally (i.t.) 100μg/10μL for LSOS and
100μg/10μLforLEHLA.D-serinewasdissolvedinsalineand
injected one bolus of 300μg/10μL.
2.4. Electrophysiological Evaluations
2.4.1. C-Fiber Reﬂex Nociceptive Test. The C-ﬁber reﬂex will
be evaluated in the normal and monoarthritic paw using
urethane (1.2g/kg i.p.) anesthetized animals. The C ﬁbers
will be stimulated by means of supramaximal electrical
shocks applied on the 4th and 5th toes territory innervated
by the sural nerve, by means of two stainless steel needles.
Then, with 0.1Hz stimulation with intensity of two times,
the electromyographic threshold will be maintained through
the whole experiment. The electromyographic activity will
be registered from the biceps femoris ipsilateral [9]. The
electromyographic responses will be loaded to a computer
provided with a digital to analog converter, and ad hoc
software and the absolute value of the integrated response
( e x p r e s s e di nV o l tp e rs e c o n d )t a k e ni nat i m ew i n d o w
opened between 150 to 450ms after the stimulus (time zero)
will constitute the C-reﬂex response. Animals with simulated
arthritis will serve as controls. This C-ﬁber activated reﬂex is
equivalent to the R-III reﬂex recorded in man, representing a
direct proportionality among subjective pain perception and
the electromyographic intensity.
2.4.2. Spinal Wind-Up. The same initial C-reﬂex protocol is
followed here. In order to evoke the synaptic potentiation
phenomena or wind-up, ten 1.0Hz stimuli will be applied.
This initial testing will be the control. For all the cases, only
values showing increment in the integral will be used. It
happens usually between the third to eighth stimuli. In order
to quantify the wind-up eﬀect, we deﬁne the term percent of
algesia as
%A l g e s i a=

WU ∗100
WUCt=0

−100

,( 1 )
where WU means the wind-up value of the normal and
monoarthritic rats in diﬀerent times; WUCt=0 means the
wind-up value of the normal rats at time zero. With this
equation, points showing positive values signify hyperalgesia
(due to the monoarthritis) and negative values meaning
analgesia.
2.5. Analysis of Results. Results were expressed as means ±
SEM., N = 6r a t si na l lg r o u p s .P<0.05 according to two
way ANOVA.
3. Results
We have studied the eﬀect of two compounds that were able
to reduce the activity of the serine racemase in vitro or in cell
cultures. Among the most eﬀective competitive inhibitors
are small amino and dicarboxylic acids like EBHA with a
Ki = 43μM and malonic acid (Ki = 71μM), among others.
Unfortunately, the last was uneﬀective in our studies up to
10μg/10μL i.t. (results not shown). L-serine-O-sulfate is one
of the aminoacids able to inhibit the serine racemase activity,
with D-cysteine and L-lysine (not tested in this work). Other
aminoacids were proven to be ineﬀective [5].
3.1. Eﬀect of LSOS and LEHA on C-Reﬂex Activity. Figure 1
shows the C-reﬂex response after the application of LSOS
(100μg/10μL) at time zero and LEHA (100μg/10μL) at
time zero (Figure 2). It can be observed that the C-response
either in normal or monoarthritic rats is constant and the
C-reﬂex paradigm is unaﬀected by the both treatments.
The former due probably to the fact that the response at
lower frequencies (enough to evoke the C-reﬂex) of the sural
nerveelectricalstimulation,involvestheactivationofAMPA/
Kainate receptors and not the NMDAr, blocked by magne-
sium ions [10].
3.2. Eﬀect of LSOS and LEHA on Wind-Up Activity. Both
compounds were able to decrease the wind-up activity in
normal and monoarthritic rats. There was a signiﬁcative
lowering in the hyperalgesia produced in the monoarthritic
rats and a progressive return to a normal condition. In
normal rats, both compounds acted as antinociceptive. In
Figure 3, the eﬀect of LSOS is depicted. At time zero, the
hyperalgesia produced by the monoarthritic condition can
beseen.TheapplicationofLSOSdiminishesthehyperalgesia
and becomes signiﬁcative from time 15 minutes. Nearly
75%ofthehyperalgesiadecrementisachievedwiththeLSOS
treatment at time 60 minutes. The normal rats showed
analgesia with respect to time zero becoming statisticallyThe Scientiﬁc World Journal 3
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Figure 1: Eﬀect of LSOS on the spinal C-reﬂex. The ﬁgure shows
the C-reﬂex response after the application of 100μg/10μL of LSOS
i.t. at time zero. Both normal and monoarthritic rat responses are
not modiﬁed by the LSOS treatment, indicating that LSOS is not
involved in the C-reﬂex response. (Values are mean ± SE, n = 6r a t s
each group).
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Figure 2: Eﬀect of LEHA on the spinal C-reﬂex. The ﬁgure shows
the C-reﬂex response after the application of 100μg/10μLo fL E H A
i.t. at time zero. Both normal and monoarthritic rat responses are
not modiﬁed by the LSOS treatment, indicating that LEHA is not
involved in the C-reﬂex response. (Values are mean ± SE, n = 6r a t s
each group).
signiﬁcant from time 15 minutes. Nearly 50% of decre-
ment is achieved at time 60 minutes. At 75min, D-serine
(300μg/10μL) is added i.t. Then, at 90min, it can be ob-
served that D-serine restitutes the hyperalgesia in mono-
arthritic rats and the analgesia in normal rats. Values
observed are not diﬀerent from those obtained at time zero.
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Figure 3: Eﬀect of LSOS on spinal wind-up. The ﬁgure shows
the eﬀect of LSOS i.t. on spinal wind-up at time zero. There is
hyperalgesia in the monoarthritic rats, due to his arthritic condi-
tion. The observed tendency is to diminish this hyperalgesia, being
statistically signiﬁcant from time 15 minutes (
∗P < 0.05, Two-way
ANOVA). On the other hand, normal rats present analgesia, being
statistically signiﬁcant from time 15 minutes reaching a value of
around 50% at time 60 minutes with respect to the control animals.
At 75min, D-serine (300μg/10μL) is injected i.t., and at 90min,
both the hyperalgesia in monoarthritic rats and analgesia in normal
rats return to the original values found at time zero. (Values are
mean ± SE, n = 6 rats each group).
The eﬀect of LEHA is shown in Figure 4. As can be seen,
the results are nearly the same. In order to be sure that both
groups of rats behave the same, the hyperalgesia observed in
the monoarthritic rats at time zero was not signiﬁcantly dif-
ferentfromthehyperalgesiaofthemonoarthriticratstreated
with LSOS. The hyperalgesia is diminished with the LEHA
treatment and becomes signiﬁcant from time 15 minutes.
In this case, the eﬀect is important achieving more than
100%ofhyperalgesiareduction,sinceattime60minutes,the
hyperalgesia becomes analgesia. The i.t. injection of D-serine
(300μg/10μL)at75minrestitutesthevaluestothezerotime.
4. Discussion
Arthritic pain constitutes a serious health problem in our
society. NMDAr plays an important role in the development
and maintenance of chronic pain. This receptor is also
involved in several other processes like learning, behavior,
and long-term synaptic plasticity in the hippocampus. At
present, among the many strategies utilized for the treatment
of chronic pain, the use of nonsteroidal anti-inﬂammatory
drugs [11] and electroacupuncture [12]a r i s e sa sp r o m i s i n g
tools. Both, unfortunately, are presenting serious drawbacks.
The ﬁrst, in long-term treatments, causes the presence of
gastrointestinal ulcers or kidney damage. The last leads
to the poorly understood mechanisms leading to elec-
troacupuncture analgesia. Both NMDA receptor blockade4 The Scientiﬁc World Journal
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Figure 4: Eﬀect of LEHA on spinal wind-up. The ﬁgure shows
the eﬀect of LEHA i.t. on spinal wind-up at time zero. There is
hyperalgesiainthemonoarthriticratsduetohisarthriticcondition.
The observed tendency is to diminish this hyperalgesia, being
statistically signiﬁcative from time 15 minutes (
∗P < 0.05, two-
way ANOVA). At 60min, the hyperalgesia turns into analgesia,
indicating that this compound is more eﬃcient than LSOS. On
the other hand, normal rats present analgesia, being statistically
signiﬁcant from 30min reaching a value of around 75% at
60min with respect to the control animals. At 75min, D-serine
(300μg/10μL) is injected i.t., and at 90min, both the hyperalgesia
in monoarthritic rats and analgesia in normal rats return to the
original values found at time zero. (Values are mean ± SE, n = 6
rats each group).
or inactivation often results in undesirable side eﬀects; for
example, if the blockade is too speciﬁc, then hallucinations is
one of the prominent side eﬀect found. On the other side,
NMDA receptor overactivation produces neuronal death
leading to brain damage [13]. Since the only intrinsic source
known so far of D-serine synthesis in the organism is the
racemization of L-serine produced by the D-serine racemase,
this pathway is a key process for the cell to obtain this amino
acid. Then, any eﬀort to lower D-serine concentration in
nociceptive synapses will result in the inhibition of the
NMDAr-mediated neuronal activity and thus producing
antinociception. The treatment with these two compounds
reduced the hyperalgesia in the monoarthritic rats, and with
a proper adjustment of dosage, we expect the complete
suppression of pain in this animal pain model. It is inter-
esting that only the wind-up was aﬀected by the treatment,
since the C-reﬂex was not aﬀected indicating that only the
NMDAr are involved in the antinociceptive eﬀect described.
We tested also malonic acid but without success, even with
a Ki = 71μM, in the order of magnitude of EBHA. Free
malonate is present at a high concentration in the rat brain
(192nmol/g wet weight) [14], but the reason why it did
not present any eﬀect on serine racemase remains to be
elucidated. Regarding the toxicity of these compounds, we
injected 500μg/10μL i.t. of both compounds by means
of a brief isoﬂurane (5% in 100% O2) anesthesia and
followed up the behavior of the rats, both normal and
monoarthritic, for 5 days. The idea was to compare the rat
behavior with the control rats by visual observation. Since
it was undistinguishable from the control rats, we assume
that the compounds at the concentration utilized were
innocuous to the rats. Finally, the fact that the drugs were
injected i.t. and not systemically and at lower levels of the
spinal cord (L5-L6), the possibility of interference of unde-
s i ra b l es i d ee ﬀects (learning, behavioral abnormalities) at the
supraspinal level is abolished. As a conclusion, we can say
that rheumatoid arthritis remains a major health problem
worldwide, with a prevalence that may amount to one case
per 100 people depending on the geographical area of the
world considered. Among other major impairing health
problems associated with rheumatoid arthritis, pain emerges
as the most commonly reported and prevalent debilitating
condition, but current therapies are still suboptimal. The use
of serine racemase inhibitors might constitute a new tool
for the treatment of this condition and applicable to other
chronic pain syndromes.
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